Office of Commercialization and Economic Development
Office of Technology Commercialization

Protection of Renal Tissues from Ischemia through Inhibition of the Proliferative Kinases CDK4 and CDK6

Technology #10-0119

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Norman Sharpless
Managed By
Jackie Quay
Director 919.966.3929
Patent Protection
US Patent 9,808,461

An inhibitor of CDK4/6 significantly reduced renal injury in a mouse model of ischemia-reperfusion injury. Acute kidney injury (AKI) is a common and costly side effect of chemotherapy characterized by sudden impairment of kidney function.  There are currently no approved therapeutics to prevent or treat AKI. CDK4/6 inhibition protects renal cells from AKI through transient G0/G1 cell cycle arrest. 
Advantages:
•  Transient protection from acute kidney injury
•  CDK4/6 inhibitors are clinically approved 
•  Applicable to chemotherapy and surgically induced AKI

Related Publications: